Cost-effectiveness analysis of zhibituo and simvastatin in treatment of hyperlipemia
Jinping Zhang
Abstract
Jinping Zhang
Abstract
Objective To explore the cost-effectiveness analysis of zhibituo and simvastatin in treatment of hyperlipemia. Methods 68 cases with hyperlipemia were divided into two groups randomly:group A were treated with imvastatin (n = 33),group B were treated with zhibituo(n = 35). The data was evaluated with eost-effectiveneas analysis. Results The cost of the two groups was 462.56 yuan and 257.60 yuan respectivdy. The effective rate was 74.28 % and 73.9.3 %respectivdy. The cost-effectiveness ratio was 6.23 and 3.48 respectively. The increased cost-effectiveness ratio of group A vs group B was 585.6. No significant differences were found in both effective rate and ADRS between two groups(P>0.05).Conclusion Zhibituo was an effective and safe drug in treating hyperlipidemia as well as simvastatin. But zhibituo was better than simvastatin based on the oost-effeetiveness analysis. Key words: Hyperlipemias; Zhibituo; Simvastation; Ecomomics, pharmaceutical
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To explore the cost-effectiveness analysis of zhibituo and simvastatin in treatment of hyperlipemia. Methods 68 cases with hyperlipemia were divided into two groups randomly:group A were treated with imvastatin (n = 33),group B were treated with zhibituo(n = 35). The data was evaluated with eost-effectiveneas analysis. Results The cost of the two groups was 462.56 yuan and 257.60 yuan respectivdy. The effective rate was 74.28 % and 73.9.3 %respectivdy. The cost-effectiveness ratio was 6.23 and 3.48 respectively. The increased cost-effectiveness ratio of group A vs group B was 585.6. No significant differences were found in both effective rate and ADRS between two groups(P>0.05).Conclusion Zhibituo was an effective and safe drug in treating hyperlipidemia as well as simvastatin. But zhibituo was better than simvastatin based on the oost-effeetiveness analysis. Key words: Hyperlipemias; Zhibituo; Simvastation; Ecomomics, pharmaceutical
Key concepts: Simvastatin, Medicine, Hyperlipidemia, Internal medicine, Significant difference, Group B, Gastroenterology, Endocrinology